NasdaqCM:FRNMBiotechs
Freenome (FRNM) Following FDA Approval Why Its 36.8x P S Still Looks Pricey
Freenome (FRNM) stock is in focus after the company and Abbott received U.S. Food and Drug Administration approval for SimpleScreen CRC, a blood based colorectal cancer screening test for average risk adults.
See our latest analysis for Freenome.
The FDA approval and upcoming U.S. launch of SimpleScreen CRC comes as Freenome trades at US$11.15, with a 30 day share price return of 3.24% and a year to date share price decline of 14.23%. The 1 year total shareholder return is 5.49%, suggesting...